Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07695740 is registered in ClinicalTrials.gov with Excyte Biopharma Ltd as lead sponsor.

NCT NCT07695740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07695740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Excyte Biopharma Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2029
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma (rrmm)